Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Ajinomoto Althea, Inc.
EIR
•Ajinomoto Althea, Inc.•November 15, 2013

Ajinomoto Althea, Inc. – FDA EIR, Nov 15, 2013

Record Details

Ajinomoto Althea, Inc. underwent an FDA Pre-Approval and Current Good Manufacturing Practice (CGMP) inspection from November 4-15, 2013, focusing on its role as a contract manufacturer of clinical and biological drug products. The inspection identified twelve significant deficiencies across several critical operational systems. In the Laboratory Control System, the company failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods. Scientifically sound specifications for materials and drug products were absent, and in-process specifications were inconsistent with final product standards. The stability program was inadequate, notably not supporting tentative expiration dates with ongoing full-shelf studies and failing to test products in their final container-closure systems. Furthermore, supplier analysis reports for components were accepted without proper validation, and representative samples were not consistently taken for incoming materials. Deficiencies in the Production System included batch records that omitted actual and theoretical yield percentages, alongside master production records lacking complete manufacturing and control instructions. The Facilities and Equipment System exhibited issues with inadequate air pressure control and equipment designs unsuitable for their intended use, cleaning, and maintenance. These violations were cited under applicable regulatory frameworks, including CGMP regulations. Following the issuance of an FDA-483 form to the President/CEO, Ajinomoto Althea committed to implementing corrections and submitting a formal written response to the District within fifteen working days.

Company
Ajinomoto Althea, Inc.
Inspection date
November 15, 2013
Product type
drugs
Office
Los Angeles District Office
Person
  • Virgilio F. Pacio (investigator)
View Company Profile

ID · b16d2094-f352-49b1-a8b5-ec22547726fe

Violation Codes10
21 CFR 211.160(b)21 CFR 211.166(b)21 CFR 211.46(b)21 CFR 211.188(b)(7)21 CFR 211.84(b)21 CFR 211.166(a)(4)21 CFR 211.166(a)(3)21 CFR 211.165(e)21 CFR 211.110(b)21 CFR 211.63

Full citation text and observation details available on the Dashboard.

Other documents for Ajinomoto Althea, Inc.
  • 483 - 2025-05-09May 9, 2025
  • 483 - 2023-09-20September 20, 2023
  • 483 - 2023-02-09February 9, 2023
  • 483 - 2023-01-16January 16, 2023
  • 483 - 2021-05-25May 25, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Ajinomoto Althea, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.